| Congestive heart failure
Synjardy vs Verquvo
Side-by-side clinical, coverage, and cost comparison for congestive heart failure.Deep comparison between: Synjardy vs Verquvo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVerquvo has a higher rate of injection site reactions vs Synjardy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Verquvo but not Synjardy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Synjardy
Verquvo
At A Glance
Oral
Once or twice daily
SGLT2 inhibitor / biguanide
Oral
Once daily
Soluble guanylate cyclase (sGC) stimulator
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Congestive heart failure
- Chronic Kidney Diseases
- Congestive heart failure
Dosing
Diabetes Mellitus, Non-Insulin-Dependent SYNJARDY: empagliflozin 10 mg/day (may increase to 25 mg/day) plus metformin HCl up to 2,000 mg/day, taken orally twice daily with meals; SYNJARDY XR: once daily with morning meal; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Congestive heart failure, Chronic Kidney Diseases Empagliflozin 10 mg/day component as part of SYNJARDY or SYNJARDY XR, taken orally; not recommended if eGFR <45 mL/min/1.73 m2.
Congestive heart failure Starting dose 5 mg orally once daily with food (2.5 mg for patients at risk of symptomatic hypotension); double dose approximately every 2 weeks to reach target maintenance dose of 10 mg once daily, as tolerated.
Contraindications
- Severe renal impairment (eGFR <30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, metformin HCl, or any excipient in SYNJARDY or SYNJARDY XR
- Concomitant use of other soluble guanylate cyclase (sGC) stimulators
- Pregnancy
Adverse Reactions
Most common (>=5%) Hypoglycemia (with sulfonylurea), urinary tract infection, nasopharyngitis, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, vitamin B12 deficiency, lower limb amputation
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, rash, urticaria, cholestatic/hepatocellular liver injury
Most common (>=5%) Hypotension, anemia
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; metformin HCl is a biguanide antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Vericiguat is a stimulator of soluble guanylate cyclase (sGC); by directly stimulating sGC independently of and synergistically with nitric oxide (NO), it augments intracellular cGMP levels, leading to smooth muscle relaxation and vasodilation, thereby addressing myocardial and vascular dysfunction associated with heart failure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Synjardy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Verquvo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (3/12) · Qty limit (9/12)
UnitedHealthcare
Synjardy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Verquvo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Synjardy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Verquvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Synjardy.
No savings programs available for Verquvo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SynjardyView full Synjardy profile
VerquvoView full Verquvo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.